VistaGen shares surge 13% after FDA grants fast track status to non-opioid pain treatment

VistaGen shares surge 13% after FDA grants fast track status to non-opioid pain treatment

VistaGen Therapeutics Inc.’s stock VTGN, +2.70% surged 13% in premarket trade Wednesday, after the company said it has been awarded U.S. Food and Drug Administration Fast Track Designation for a non-opioid pain treatment. The FDA has granted the designation, which aims to expedite the review of drugs for diseases with high unmet needs, to VistaGen’s AV-101 small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist, which aims to treat neuropathic pain without causing sedation. Drug companies are racing to create a non-opioid pain treatment, given the current crisis affecting many communities with high numbers of opioid overdoses and deaths. VistaGen hares have gained 37% in 2018, while the S&P 500 SPX, -0.04% has gained 9%.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.

Related posts